DoorDash is now valued at $12.6bn after securing funding in a series G round backed by SoftBank Vision Fund, taking its total funding to nearly $2bn.

The T-Cell therapy developer has received funding in a Gilead Sciences-backed series B round led by Fidelity Management and Research.

UnityPoint Health has launched a corporate venturing arm, UnityPoint Health Ventures Innovation Fund, that will invest in areas such as digital health and medical devices.

GV participated in a round that will enable the on-demand recruitment platform to accelerate its expansion across the US.

Online investment management service Wealthsimple secured $74.6m in an Allianz X-led round that also featured long-standing investor Power Financial.

UCB Ventures and Alphabet unit GV took part in the RNA-targeting gene therapy developer's first publicly disclosed funding round, which was led by Arch Venture Partners.

GuideWell Mutual, Blue Shield California and existing backer Premera Blue Cross all invested in the healthcare prediction platform developer.

Cambridge Innovation Capital has celebrated an exit as Bicycle Therapeutics successfully lists in the US.

Mars Petcare-backed vegan dog food producer Wild Earth has collected $11m in a series A round that took its total funding to $16m.

Freshworks has paid an undisclosed amount for the customer success management software developer, allowing Salesforce Ventures to exit.